This session at ESC 2025 highlighted advances in hypertension treatment exhibiting quadpill efficacy, stroke risk reduction, dapagliflozin benefits, telemonitoring, spironolactone’s mortality impact, & effect of RAAS drug on brain health.

The session highlights the latest research on efficacy and safety of glucagon like peptide-1agonists and sodium-glucose cotransporter-2 inhibitors in various disease including atrial fibrillation and high-risk diabetes.

Children born to mothers with hypertensive disorders of pregnancy had higher unadjusted risks of autism (OR 1.65), attention-deficit/hyperactivity disorder (1.27), intellectual disability (1.77), global developmental delay (1.77), and lower IQ (MD −2.20). Autism and developmental delay weakened after adjustments, but reduced IQ persisted, underscoring the need for early monitoring and intervention in these patients.

A study using 14 years of data found that patients ≥45 years with multiple psychiatric disorders had markedly higher odds of developing dementia. Two comorbidities doubled dementia risk (OR 2.3), while four raised it 11-fold (OR 11.1) vs. one disorder. Co-occurrence of mood and anxiety disorders carried the highest probability (48% to 89.6%). Early cognitive screening may enable timely risk reduction strategies.

In 848 adults with T1D using continuous glucose monitoring, time below range (TBR) alone did not predict 1-year incidence of severe hypoglycemic events (SHE). Over a year, 11.7% experienced SHE, but risk rose only in those with impaired awareness of hypoglycemia (IAH) along with high TBR70>6% (70 mg/dl; OR 3.32) or TBR54≥1% (54 mg/dl; OR 2.99). Assessing IAH alongside TBR could help identify high-risk patients.